Literature DB >> 31977254

Artificial Intelligence Tool for Optimizing Eligibility Screening for Clinical Trials in a Large Community Cancer Center.

J Thaddeus Beck1, Melissa Rammage2, Gretchen P Jackson2, Anita M Preininger2, Irene Dankwa-Mullan2, M Christopher Roebuck3, Adam Torres4, Helen Holtzen1, Sadie E Coverdill2, M Paul Williamson5, Quincy Chau5, Kyu Rhee2, Michael Vinegra5.   

Abstract

PURPOSE: Less than 5% of patients with cancer enroll in clinical trials, and 1 in 5 trials are stopped for poor accrual. We evaluated an automated clinical trial matching system that uses natural language processing to extract patient and trial characteristics from unstructured sources and machine learning to match patients to clinical trials. PATIENTS AND METHODS: Medical records from 997 patients with breast cancer were assessed for trial eligibility at Highlands Oncology Group between May and August 2016. System and manual attribute extraction and eligibility determinations were compared using the percentage of agreement for 239 patients and 4 trials. Sensitivity and specificity of system-generated eligibility determinations were measured, and the time required for manual review and system-assisted eligibility determinations were compared.
RESULTS: Agreement between system and manual attribute extraction ranged from 64.3% to 94.0%. Agreement between system and manual eligibility determinations was 81%-96%. System eligibility determinations demonstrated specificities between 76% and 99%, with sensitivities between 91% and 95% for 3 trials and 46.7% for the 4th. Manual eligibility screening of 90 patients for 3 trials took 110 minutes; system-assisted eligibility determinations of the same patients for the same trials required 24 minutes.
CONCLUSION: In this study, the clinical trial matching system displayed a promising performance in screening patients with breast cancer for trial eligibility. System-assisted trial eligibility determinations were substantially faster than manual review, and the system reliably excluded ineligible patients for all trials and identified eligible patients for most trials.

Entities:  

Mesh:

Year:  2020        PMID: 31977254     DOI: 10.1200/CCI.19.00079

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


  11 in total

1.  Clinical Data Abstraction: A Research Study.

Authors:  Valerie J M Watzlaf; Patty T Sheridan; Amal A Alzu'bi; Laura Chau
Journal:  Perspect Health Inf Manag       Date:  2021-03-15

2.  Applying advanced technologies to improve clinical trials: a systematic mapping study.

Authors:  Esther Nanzayi Ngayua; Jianjia He; Kwabena Agyei-Boahene
Journal:  Scientometrics       Date:  2020-11-21       Impact factor: 3.238

3.  A systematic review on natural language processing systems for eligibility prescreening in clinical research.

Authors:  Betina Idnay; Caitlin Dreisbach; Chunhua Weng; Rebecca Schnall
Journal:  J Am Med Inform Assoc       Date:  2021-12-28       Impact factor: 4.497

4.  Practical Aspects of Implementing and Applying Health Care Cloud Computing Services and Informatics to Cancer Clinical Trial Data.

Authors:  Jay G Ronquillo; William T Lester
Journal:  JCO Clin Cancer Inform       Date:  2021-08

5.  Accuracy of an Artificial Intelligence System for Cancer Clinical Trial Eligibility Screening: Retrospective Pilot Study.

Authors:  Tufia Haddad; Jane M Helgeson; Katharine E Pomerleau; Anita M Preininger; M Christopher Roebuck; Irene Dankwa-Mullan; Gretchen Purcell Jackson; Matthew P Goetz
Journal:  JMIR Med Inform       Date:  2021-03-26

Review 6.  An overview of artificial intelligence in oncology.

Authors:  Eduardo Farina; Jacqueline J Nabhen; Maria Inez Dacoregio; Felipe Batalini; Fabio Y Moraes
Journal:  Future Sci OA       Date:  2022-02-10

Review 7.  Application of Artificial Intelligence in Discovery and Development of Anticancer and Antidiabetic Therapeutic Agents.

Authors:  Amal Alqahtani
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-25       Impact factor: 2.650

8.  Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms.

Authors:  Kamal S Saini; Begoña de Las Heras; Ruth Plummer; Victor Moreno; Marco Romano; Javier de Castro; Philippe Aftimos; Judy Fredriksson; Gouri Shankar Bhattacharyya; Martin Sebastian Olivo; Gaia Schiavon; Kevin Punie; Jesus Garcia-Foncillas; Ernesto Rogata; Richie Pfeiffer; Cecilia Orbegoso; Kenneth Morrison; Giuseppe Curigliano; Lynda Chin; Monika Lamba Saini; Øystein Rekdal; Steven Anderson; Javier Cortes; Manuela Leone; Janet Dancey; Chris Twelves; Ahmad Awada
Journal:  JCO Glob Oncol       Date:  2020-09

Review 9.  Molecular-based precision oncology clinical decision making augmented by artificial intelligence.

Authors:  Jia Zeng; Md Abu Shufean
Journal:  Emerg Top Life Sci       Date:  2021-12-21

Review 10.  The Role of Artificial Intelligence in Early Cancer Diagnosis.

Authors:  Benjamin Hunter; Sumeet Hindocha; Richard W Lee
Journal:  Cancers (Basel)       Date:  2022-03-16       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.